1. Home
  2. NOMA vs GRML Comparison

NOMA vs GRML Comparison

Compare NOMA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOMADAR Corp.

NOMA

NOMADAR Corp.

N/A

Current Price

$1.16

Market Cap

30.2M

ML Signal

N/A

Logo Greenland Mines Ltd. Common Stock

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$4.02

Market Cap

29.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NOMA
GRML
Founded
2023
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.2M
29.2M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
NOMA
GRML
Price
$1.16
$4.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.9K
★ 2.3M
Earning Date
11-23-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.25
EPS
★ N/A
N/A
Revenue
★ $6,376.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.16
52 Week High
$10.00
$18.21

Technical Indicators

Market Signals
Indicator
NOMA
GRML
Relative Strength Index (RSI) 30.84 40.68
Support Level N/A $0.28
Resistance Level $1.88 $7.53
Average True Range (ATR) 0.18 0.41
MACD -0.05 -0.14
Stochastic Oscillator 7.93 17.19

Price Performance

Historical Comparison
NOMA
GRML

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: